Drug intelligence / Profile preview

ELU700

Development stage: Preclinical
Lead developer: Eluciderm
Modality: Small Molecules

Overview

ELU700 is a small molecule inhibitor of Poly(ADP-ribose) polymerase (PARP) being developed by Eluciderm. It is categorized as an NCI (National Cancer Institute) candidate and is currently in the preclinical stage of development. The drug is intended for the treatment of leukemia and malignant melanoma. By inhibiting PARP, ELU700 interferes with the repair of single-strand DNA breaks, leading to the accumulation of DNA damage and eventual cell death in tumor cells, particularly those with deficiencies in alternative DNA repair pathways.

Other names: ELU700ELU-700ELU 700

Targets

PARP1 (Poly (adp-ribose) polymerase 1)

Beyond the preview

Go deeper on ELU700.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELU700.

Explore the full profile